| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/29/1997 | US5624685 High polymer gel and vascular lesion embolizing material comprising the same |
| 04/24/1997 | WO1997014800A1 Novel saliva binding protein |
| 04/24/1997 | WO1997014439A1 Pharmaceutical composition containing a blood-brain barrier transport enhancer |
| 04/24/1997 | WO1997014438A1 Production of analgesic synergy by co-administration of sub-analgesic doses of a mu opioid agonist and a kappa-2 opioid agonist |
| 04/24/1997 | WO1997014437A1 Methods of reducing apolipoprotein e4-induced inhibition of neuron remodeling |
| 04/24/1997 | WO1997014432A1 Modulation of integrin-mediated signal transduction |
| 04/24/1997 | WO1997014425A1 Two novel genes from psoriatic epidermis: psoriastatin type i and psoriastatin type ii |
| 04/24/1997 | WO1997014423A1 Medicament for treating arterial occlusive vascular diseases, micro-angiopathies and micro-circulatory disturbances |
| 04/24/1997 | WO1997014416A1 Conjugates useful in the treatment of benign prostatic hyperplasia |
| 04/24/1997 | WO1997009348A3 Orphan receptor |
| 04/24/1997 | WO1996040055A3 Biological agent compositions |
| 04/24/1997 | DE19538666A1 Arzneimittel zur Behandlung von arteriellen Verschlußkrankheiten, Mikroangiopathien und Mikrozirkulationsstörungen Drugs for treatment of arterial occlusive diseases, microangiopathy and microcirculatory disturbances |
| 04/24/1997 | CA2235071A1 Analgesic immediate and controlled release pharmaceutical composition |
| 04/24/1997 | CA2234968A1 Topically applied, structural cellulite treatments |
| 04/24/1997 | CA2233848A1 Methods of reducing apolipoprotein e4-induced inhibition of neuron remodeling |
| 04/24/1997 | CA2207973A1 Modulation of integrin-mediated signal transduction |
| 04/23/1997 | EP0769300A2 Antiemetic composition containing an NK-1 receptor antagonists |
| 04/23/1997 | EP0769293A2 Use of at least a beta-adrenergic agonist as an antagonist of substance P |
| 04/23/1997 | EP0769292A1 Products for dermatologic care and cosmetics |
| 04/23/1997 | EP0769148A1 Improved methods for the determination and adjustment of prolactin daily rhythms |
| 04/23/1997 | EP0769146A2 Screening for nuc inhibitors |
| 04/23/1997 | EP0769060A1 Fas associated proteins |
| 04/23/1997 | EP0769025A1 Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown |
| 04/23/1997 | EP0769006A1 Small molecule inhibitors of rotamase enzyme activity |
| 04/23/1997 | EP0769005A2 Pla 2? inhibitors and their use for inhibition of intestinal cholesterol absorption |
| 04/23/1997 | EP0768895A1 Camptothecin drug combinations and medicaments with reduced side effects |
| 04/23/1997 | EP0768890A1 Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain |
| 04/23/1997 | EP0768889A1 Cancer therapy using lymphotoxin |
| 04/23/1997 | EP0768883A1 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| 04/23/1997 | EP0768880A1 Tacrine pharmaceutical compositions |
| 04/23/1997 | EP0768877A1 Antikeratolytic-wound healing compositions and methods for preparing and using same |
| 04/23/1997 | EP0768875A1 Nitric oxide synthase inhibitors for inhibiting the production of airway mucus |
| 04/23/1997 | EP0768819A1 Combined virustatic antimediator (covam) treatment of common colds |
| 04/23/1997 | EP0655927B1 Interleukin-4 stimulated t lymphocyte cell death |
| 04/23/1997 | EP0563249B1 Targeting of therapeutic agents using polysaccharides |
| 04/23/1997 | CN1148389A Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists |
| 04/23/1997 | CN1148344A New oral pharmaceutical dosage form |
| 04/23/1997 | CN1148337A Compound active at a novel site on receptor-operated calcium channels usefull for treatment of neurological disorders and diseases |
| 04/22/1997 | US5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
| 04/22/1997 | US5622980 Oral compositions of H2-antagonists |
| 04/22/1997 | US5622952 Glycine receptor antagonists and the use thereof |
| 04/17/1997 | WO1997013845A2 Phosphopantetheinyl transferases and uses thereof |
| 04/17/1997 | WO1997013527A1 Treatments of helicobacter pylori infections |
| 04/17/1997 | WO1997013514A1 Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy |
| 04/17/1997 | WO1997013513A1 At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
| 04/17/1997 | WO1997013506A1 η-RAR ANTAGONIST LIGAND OR α-RAR AGONIST LIGAND AS AN APOPTOSIS INHIBITOR |
| 04/17/1997 | WO1997013505A2 USE OF A η-RAR-SPECIFIC AGONIST LIGAND TO INCREASE APOPTOSIS RATE |
| 04/17/1997 | WO1997005870A3 Use of griseofulvin for inhibiting the growth of cancers |
| 04/17/1997 | WO1997005864A3 Use of l-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs |
| 04/17/1997 | WO1997005862A3 Use of basic amino acids and derivatives for lowering ceramide levels |
| 04/17/1997 | CA2231561A1 Use of a .gamma.-rar-specific agonist ligand to increase apoptosis rate |
| 04/16/1997 | EP0767669A1 New pharmaceutical preparation for pain management |
| 04/16/1997 | EP0767662A1 Dopamine d 1? agonists for the treatment of dementia |
| 04/16/1997 | EP0767660A1 Methods and formulations for modulating the human sexual response |
| 04/16/1997 | EP0601001B1 Liquid food product containing 3-guanidinopropionic acid |
| 04/16/1997 | EP0536282B1 Meducament for treating prostatic adenocarcinoma |
| 04/16/1997 | CN1147768A Compositions comprising DNA damaging agents and P53 |
| 04/16/1997 | CN1147767A Use of serotonin antagonists (5HT3) for treating fibromyalgia |
| 04/15/1997 | US5621012 Active compound combinations having a content of glyceryl alkyl ethers and cosmetic and dermatological formulations comprising such active compound combinations |
| 04/15/1997 | US5621006 Topically applying in a vehicle, e.g. hydroxyacids, ketoacids and salts, esters thereof |
| 04/15/1997 | US5621001 Methods for administration of taxol |
| 04/15/1997 | US5620979 Treating neuronal loss associated with stroke, ischemia, central nervous system trauma, hypoglycemia or surgery |
| 04/15/1997 | US5620975 Pharmaceutical composition and method for the control of hypertension |
| 04/15/1997 | US5620964 Oligosaccharides; eliminating helicobacter from stomach |
| 04/15/1997 | US5620921 Treating keratoconjunctivitis sicca by topical application of androgen to ocular surface or immediate vicinity of eye |
| 04/15/1997 | US5619984 Dry powder inhalation device having a powder-loaded elongate carrier |
| 04/15/1997 | CA2104229C Opiate receptor antagonist modulates movement disorder |
| 04/10/1997 | WO1997012984A1 COMPOUND HAVING SEQUENCE HOMOLOGY WITH LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 (Lp-PLA2)/PAF ACETYL HYDROLASE |
| 04/10/1997 | WO1997012898A1 Novel platelet activation protein |
| 04/10/1997 | WO1997012853A1 Dimer-selective rxr modulators and methods for their use |
| 04/10/1997 | WO1997012634A1 A NOVEL COMBINATION OF A β-RECEPTOR BLOCKER AND AN OPIOID |
| 04/10/1997 | WO1997012633A1 Dendritic cell stimulatory factor |
| 04/10/1997 | WO1997012630A1 Combination of temozolomide and alpha-ifn for the treatment of advanced cancer |
| 04/10/1997 | WO1997012624A1 Novel peptides |
| 04/10/1997 | WO1997012623A1 Methods and compositions for viral enhancement of cell killing |
| 04/10/1997 | WO1997012617A1 Proteins involved in targeting of peptidyl transfer center, and corresponding therapeutic agents and methods |
| 04/10/1997 | WO1997012612A1 Compositions of melatonin and analgetic agents and methods of use thereof |
| 04/10/1997 | WO1997009998A3 Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors |
| 04/10/1997 | CA2234229A1 Proteins involved in targeting of peptidyl transfer center, and corresponding therapeutic agents and methods |
| 04/10/1997 | CA2234060A1 Methods and compositions for viral enhancement of cell killing |
| 04/10/1997 | CA2233994A1 Novel platelet activation protein |
| 04/10/1997 | CA2233888A1 Dimer-selective rxr modulators and methods for their use |
| 04/10/1997 | CA2233544A1 Combination temozolomide and alpha-ifn for the treatment of advanced cancer |
| 04/10/1997 | CA2233272A1 Novel peptides |
| 04/10/1997 | CA2232865A1 The use of flt3 ligand to generate dendritic cells |
| 04/10/1997 | CA2231557A1 Compositions of melatonin and analgetic agents and methods of use thereof |
| 04/09/1997 | EP0766966A2 Method of treating insulin resistance |
| 04/09/1997 | EP0766960A1 External preparations for treating dermatoses |
| 04/09/1997 | CN1147204A Use of spiramycin for treating |
| 04/08/1997 | US5618850 Hydroxy-acid cosmetics |
| 04/08/1997 | US5618846 Treatment method for cancer |
| 04/08/1997 | US5618841 Includes an antimicrobial acid buffer |
| 04/08/1997 | US5618840 Prevention growth of helicobacter |
| 04/08/1997 | US5618824 Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
| 04/08/1997 | US5618814 Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds |
| 04/08/1997 | US5618803 Targeted drug delivery via phosphonate derivatives |
| 04/08/1997 | US5618564 Composition for the treatment of helicobacter pylori infection |
| 04/08/1997 | US5618557 Prophylactic treatment of allergic contact dermatitis |
| 04/03/1997 | WO1997012246A1 Tumour-specific p450 protein |
| 04/03/1997 | WO1997012055A1 Product and process to regulate actin polymerization |